Key result
Hydrodynamics-based delivery of IL-22-Ig gene therapy effectively suppressed experimental autoimmune myocarditis in rats by decreasing inflammatory gene expression in noncardiomyocytic cells.
Why the study?
Does IL-22-Ig gene therapy ameliorate experimental autoimmune myocarditis in rats?
Population
Rats with experimental autoimmune myocarditis (EAM) immunized on day 0
Comparison
pCAGGS-IL-22-Ig using hydrodynamics-based gene… vs pCAGGS-Ig using hydrodynamics-based gene…
Design
Preclinical
Follow-up
17 days
Authors
Loading...
IL-22-Ig gene therapy merits further preclinical testing in myocarditis models; leaves open translation to human autoimmune disease.
Does IL-22-Ig gene therapy ameliorate experimental autoimmune myocarditis in rats?
IL-22-Ig gene therapy suppresses experimental autoimmune myocarditis in rats, likely by reducing inflammatory gene expression in noncardiomyocytic cells.
Chang et al. (2006) studied Experimental autoimmune myocarditis. IL-22-Ig gene therapy (pCAGGS-IL-22-Ig) vs. pCAGGS-Ig (control) was evaluated on Control of experimental autoimmune myocarditis (heart weight to body weight ratio and myocarditis area). Hydrodynamics-based delivery of IL-22-Ig gene therapy effectively suppressed experimental autoimmune myocarditis in rats by decreasing inflammatory gene expression in noncardiomyocytic cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: